- Home
- TDUP vs VIR Comparison
TDUP vs VIR Comparison
Compare TDUP & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- VIR
- Stock Information
- Founded
- TDUP 2009
- VIR 2016
- Country
- TDUP United States
- VIR United States
- Employees
- TDUP N/A
- VIR N/A
- Industry
- TDUP Catalog/Specialty Distribution
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- VIR Health Care
- Exchange
- TDUP Nasdaq
- VIR Nasdaq
- Market Cap
- TDUP 856.1M
- VIR 844.9M
- IPO Year
- TDUP 2021
- VIR 2019
- Fundamental
- Price
- TDUP $7.58
- VIR $5.13
- Analyst Decision
- TDUP Buy
- VIR Strong Buy
- Analyst Count
- TDUP 3
- VIR 7
- Target Price
- TDUP $7.25
- VIR $32.86
- AVG Volume (30 Days)
- TDUP 2.5M
- VIR 1.1M
- Earning Date
- TDUP 08-04-2025
- VIR 07-31-2025
- Dividend Yield
- TDUP N/A
- VIR N/A
- EPS Growth
- TDUP N/A
- VIR N/A
- EPS
- TDUP N/A
- VIR N/A
- Revenue
- TDUP $266,789,000.00
- VIR $20,861,000.00
- Revenue This Year
- TDUP $12.30
- VIR N/A
- Revenue Next Year
- TDUP $7.59
- VIR N/A
- P/E Ratio
- TDUP N/A
- VIR N/A
- Revenue Growth
- TDUP 7.96
- VIR N/A
- 52 Week Low
- TDUP $0.50
- VIR $4.32
- 52 Week High
- TDUP $8.75
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- TDUP 48.74
- VIR 48.62
- Support Level
- TDUP $7.22
- VIR $5.00
- Resistance Level
- TDUP $7.98
- VIR $5.35
- Average True Range (ATR)
- TDUP 0.42
- VIR 0.24
- MACD
- TDUP -0.16
- VIR 0.02
- Stochastic Oscillator
- TDUP 13.04
- VIR 31.21
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.